Tempest Therapeutics, Inc.

NASDAQ (USD): Tempest Therapeutics, Inc. (TPST)

Last Price

0.919

Today's Change

-0.004 (0.43%)

Day's Change

0.895 - 0.935

Trading Volume

811,466

Profile
TPST

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Stephen R. Brady J.D., LLM Mr. Stephen R. Brady J.D., LLM

Full Time Employees:  17 17

IPO Date:  2012-11-12 2012-11-12

CIK:  0001544227 0001544227

ISIN:  US87978U1088 US87978U1088

CUSIP:  87978U108 87978U108

Beta:  -2.78 -2.78

Last Dividend:  0.00 0.00

Dcf Diff:  -0.30 -0.30

Dcf:  1.20 1.20

Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Address

7000 Shoreline Court,
South San Francisco, CA 94080, US

415 798 8589

http://www.tempesttx.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment